Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy

Conditions:   Metastatic Head and Neck Carcinoma;   Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Oral Cavity Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7;   Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7;   Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Unresectable Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Cabozantinib;   Biological: Pembrolizumab
Sponsors:   Emory University;   Exelixis
Not yet recruiting

http://ift.tt/2HEEPxF